Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

Home

QTTB

Q

Q32 Bio Inc. (QTTB)

NCM – Цена в реальном времени. Валюта: USD

7.25

+0.11 (1.54%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

6.90

-0.35 (-4.83%)

После закрытия: Mar 27, 2026, 7:23 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Видео

No Data

There is no data to display

Пресс-релизы

Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update

-- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; 36-week topline data readout expected in mid-2026 -- -- Completed $10.5 million registered direct offering (RDO) -- -- Completed asset sale of Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics to further enable Company's strategic focus on advancing bempikibart for alopecia areata (AA) -- -- Cash and cash equivalents of $48.3 million as of December 31, 2025, combined with gross proceeds from RDO and guaranteed near-term milestone payments from ADX-097 asset sale, expected to provide financial runway into Q4'27 -- WALTHAM, Mass., March 10, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today reported financial results for the quarter ended December 31, 2025, and provided recent corporate updates.

Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

WALTHAM, Mass., Feb. 18, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 2:00 p.m.

Q32 Bio Announces $10.5 Million Registered Direct Offering

Q32 Bio Announces $10.5 Million Registered Direct Offering

WALTHAM, Mass., Feb. 17, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced a $10.5 million registered direct offering.

Q32 Bio Sells Complement Inhibitor ADX-097

Q32 Bio Sells Complement Inhibitor ADX-097

-- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata -- -- $12 million in upfront and guaranteed near-term milestone payments expected to extend cash runway into the second half of 2027 -- -- Eligible to receive up to a total of $592 million including the $12 million in upfront and near-term payments upon achievement of certain development, regulatory and commercial milestones and eligible for tiered royalties up to a mid-teen percent of annual net sales -- -- Q32 Bio retains wholly owned tissue-targeted complement inhibitor platform, including ADX-096 and other remaining early-stage assets; continuing to evaluate strategic options for these programs -- WALTHAM, Mass. , Dec. 1, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics, Inc. (NASDAQ: AKBA) ("Akebia").